- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04003649
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To examine and describe the safety and feasibility of nivolumab plus ipilimumab as neoadjuvant therapy. (Arm 1) II. To examine and describe the safety and feasibility of IL13Ralpha2-CAR T cell plus nivolumab as adjuvant therapy. (Arms 1 and 2) III. To provide IL13Rα2-CAR T cell therapy for subjects who are unable to wait for randomization into Arms 1 and 2. This arm will provide additional safety data provided in COH IRB 13384 for the set dose schedule. (Arm 3) III. In arms determined to be safe and feasible, a selection design based on two Southwest Oncology Group (SWOG) two stage designs will be used to assess which arm(s) goes on for further study based on survival rate at 9 months.
SECONDARY OBJECTIVES:
I. Describe persistence, expansion and phenotype of endogenous and IL13Ralpha2-CAR CAR T cells in tumor cyst fluid (TCF), peripheral blood (PB), and cerebral spinal fluid (CSF).
II. Describe cytokine levels (PB, TCF, CSF) over the study period for each arm. (Arm 1 or Arm 2).
III. Estimate disease response rates. IV. Estimate time to progression. V. Estimate median overall survival (OS).
VI. In study participants who have completed the adjuvant dose-limiting toxicity (DLT) period:
VIa. Estimate the mean change from baseline in quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C)30 and EORTC QLQ Brain Cancer Patients (BN-20) survey scale, domain and item scores during and post treatment.
VIb. Assess if the area under the curve (AUC) for CD3 T cells, IFNgamma and IP-10 for the DLT period is greater in one arm versus (vs.) the other.
VII. In study participants who undergo an additional biopsy/resection or autopsy:
VIIa. Evaluate CAR T cell persistence in the tumor tissue and the location of the CAR T cells with respect to the injection, and VIIb. Evaluate IL13Ralpha2 antigen and PD-L1 levels on tumor tissue pre and post CAR T cell therapy.
VIII. Use biomathematical modeling of tumor growth to evaluate benefit of treatment.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (intracranial intraventricular [ICV]/intracranial intratumoral [ICT]) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
ARM II: Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
ARM III: Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (intracranial intraventricular [ICV]/intracranial intratumoral [ICT]) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.
After completion of study treatment, patients are followed up at 30 days, 3, 6, and 12 months, and then annually for 15 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Principal Investigator:
- Behnam Badie
-
Contact:
- Behnam Badie
- Phone Number: 89393 626-256-4673
- Email: neurosurgerymail@coh.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria Informed Consent and Willingness to Participate
- 1. Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines.
- 2. Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval. Age Criteria, Performance status
- 3. Ages ≥18 years
- 4. KPS ≥ 60%, ECOG ≤ 2
- 5. Life expectancy ≥ 4 weeks Nature of Illness and Illness Related Criteria
- 6. Histologically confirmed diagnosis of WHO classification grade IV GBM, or has a prior histologicallyconfirmed diagnosis of a grade II or III glioma and now has radiographic progression consistent with a grade IV GBM after completing standard therapy.
- 7. Relapsed/refractory disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy, and ≥ 12 weeks after completion of front-line radiation therapy.
- 8. COH Clinical Pathology confirms IL13Rα2+ tumor expression by IHC at the initial tumor presentation or recurrent disease (H-score > 50; reference Appendix B)
- 9. Participants with a known history of congestive heart failure (CHF) or cardiac symptoms consistent with NYHA classification III-IV within 6 months prior to Day 1 of protocol treatment, cardiomyopathy, myocarditis, Myocardial Infarction (MI), exposure to cardiotoxic medications or with clinical history suggestive of the above must have an EKG and Echocardiogram (ECHO) performed within 42 days prior to registration and as clinically indicated while on treatment. Clinical Laboratory and Organ Function Criteria (To be performed within 14 days prior to leukapheresis unless otherwise stated.
- 10. WBC > 2000 /dl (or ANC ≥ 1,000/mm3)
- 11. Platelets ≥ 75,000/mm3
- 12. Fasting Blood glucose within ULN
- 13. Total bilirubin ≤ 1.5 ULN
- 14. AST ≤ 2.5x ULN
- 15. ALT ≤ 2.5x ULN
- 16. Serum creatinine ≤1.6 mg/dL
- 17. O2 saturation ≥ 95% on room air
18. Seronegative for HIV Ag/Ab combo, Hepatitis C Ab*, active HBV (Surface Antigen Negative), Hepatitis A Virus IgM Antibody
*If positive, Hepatitis C RNA quantitation must be performed.
- 19. Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be
- 20. Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of nivolumab and/or 3 months after the last cycle of CAR T cells.
Exclusion Criteria Prior and concomitant therapies
- 1. Prior CTLA-4, PD-1 or PD-L1 inhibitor therapy.
- 2. Participant is steroid-dependent, requiring more than 6 mg of dexamethasone per day at the time of enrollment.
- 3. Participant has not yet recovered from toxicities of prior therapy. Other illnesses or conditions
- 4. History of or active autoimmune disease
- 5. Uncontrolled seizure activity and/or clinically evident progressive encephalopathy
- 6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
- 7. Active diarrhea
- 8. Clinically significant uncontrolled illness
- 9. Active infection requiring antibiotics
- 10. Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
- 11. Other active malignancy
- 12. Females only: Pregnant or breastfeeding
- 13. Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures. Noncompliance
- 14. Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)
Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14.
Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week.
Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Ancillary studies
Given IV
Other Names:
Given ITV/ITC
Other Names:
|
Experimental: Arm II (nivolumab, IL13Ra2 CAR T cells)
Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week.
Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Ancillary studies
Given ITV/ITC
Other Names:
|
Experimental: Arm III (IL13Ra2 CAR T cells)
Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week.
Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.
|
Ancillary studies
Other Names:
Ancillary studies
Given ITV/ITC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 15 years
|
Will assess dose limiting toxicity and all toxicities.
Toxicity is the primary endpoint and will be assessed using the National Cancer Institute (NCI)'s Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Rates and associated 95% Clopper and Pearson binomial confidence limits (95% confidence interval [CI]) will be estimated for participants' experiencing dose limiting toxicity (DLT) during neoadjuvant treatment period (DLT period 1), during adjuvant treatment period (DLT period 2), neo-adjuvant and adjuvant feasibility, as well as survival at 9 months.
All toxicities and side effects will be summarized in tables by dose, time period, organ, and severity.
|
Up to 15 years
|
Dose-limiting toxicity (DLT)
Time Frame: Up to 28 days
|
A toxicity that causes side effects that are serious enough to prevent an increase in dose or level of that treatment.
|
Up to 28 days
|
Feasibility (neoadjuvant therapy)
Time Frame: Up to 14 days
|
As measured by the ability of patients receive ipilimumab/nivolumab (> 80% of the assigned doses) and undergo undergo surgery so that they can go on to receive the first dose of CAR T cells.
|
Up to 14 days
|
Feasibility (adjuvant therapy)
Time Frame: Up to 28 days
|
Defined as the ability of patients to complete 4 cycles of CAR T infusions (> 80% of the assigned dose) and 2 doses of nivolumab.
|
Up to 28 days
|
Overall Survival
Time Frame: At 9 months
|
The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
|
At 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T cell levels
Time Frame: Up to 15 years
|
Will assess chimeric antigen receptor (CAR) T and endogenous T cell levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebral spinal fluid (CSF) (absolute number per ul by flow).
Statistical and graphical methods will be used to describe persistence and expansion.
|
Up to 15 years
|
Cytokine levels in TCF, PB, and CSF
Time Frame: Up to 15 years
|
Statistical and graphical methods will be used to describe persistence and expansion.
|
Up to 15 years
|
Disease response
Time Frame: Up to 15 years
|
By Response Assessment in Neuro-Oncology (RANO) criteria with the need for Avastin as an additional indicator of progression.
|
Up to 15 years
|
Time to progression
Time Frame: Up to 15 years
|
Progression is defined by RANO with the need for Avastin as an additional indicator of progression.
|
Up to 15 years
|
Overall survival (OS)
Time Frame: Up to 15 years
|
Kaplan Meier methods will be used to estimate median OS and graph the results.
|
Up to 15 years
|
Quality of life (QOL)
Time Frame: Up to 15 years
|
Will estimate the mean and standard error for change from baseline during treatment and post treatment in the quality of life functioning scale, symptom scale and item scores from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the domain scale and items scores from the Quality of Life Questionnaire Brian Tumor Patients 20.
Will be estimated for each treatment arm.
|
Up to 15 years
|
Area under the curve (AUC) for CD3, IFNgamma, and IP-10 levels over time for the DLT evaluation period
Time Frame: Up to 28 days
|
A two-tailed two-sample Students T test with a 0.05 level of significance will be used to determine if the AUCs over the adjuvant treatment DLT period (DLT period 2) for CD3, IFNgamma, and IP-10 are higher in one arm over the other.
|
Up to 28 days
|
CAR T and endogenous cells detected in tumor tissue
Time Frame: Up to 15 years
|
By immunohistochemistry.
|
Up to 15 years
|
IL13Ralpha2 antigen expression levels in tumor tissue
Time Frame: Up to 15 years
|
By pathology H score.
|
Up to 15 years
|
PD-L1 levels on tumor cells
Time Frame: Pre- and post-therapy
|
By flow cytometry
|
Pre- and post-therapy
|
Biomathematical modeling of tumor growth
Time Frame: Up to 15 years
|
Will assess perfusion and growth parameters based on serial brain magnetic resonance imaging (MRI)s.
|
Up to 15 years
|
Progression free survival (PFS)
Time Frame: Up to 15 years
|
Kaplan Meier methods will be used to estimate median PFS and graph the results.
|
Up to 15 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Behnam Badie, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Ipilimumab
Other Study ID Numbers
- 18251 (Other Identifier: City of Hope Medical Center)
- NCI-2018-02764 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R01CA236500 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliomatosis Cerebri | Recurrent Childhood GliosarcomaUnited States
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting